Tom Maniatis, PhD, Evnin Family Scientific Director and CEO of the New York Genome Center (NYGC) was recently interviewed by Brian Gormley of The Wall Street Journal on the impact of new, lower-cost DNA-sequencing technologies on clinical care and research.
Access the full article here.
